Extended lotilaner 0.25% therapy shows meibomian gland benefits

Published on June 6, 2025
At the 2025 ASCRS meeting, Mitch Shultz, MD, presented compelling new findings from a 12-week clinical trial investigating the impact of lotilaner 0.25% ophthalmic solution on meibomian gland function.
Continue reading on website
Other news

New York Eye and Ear Infirmary of Mount Sinai Opens Comprehensive Center for Refractive Solutions in New York City

June 6, 2025
NEW YORK—New York Eye and Ear Infirmary of Mount Sinai (NYEE) has announced the opening of the Center for Refractive Solutions—the first in New York City and one of few in the United States—that offers comprehensive and innovative treatment options for those who require refractive correction. This includes premium cataract and intraocular lens surgery, and corneal refractive procedures such as LAS

University of Bristol researchers compile new clinical guidance for uveitis

June 6, 2025
Scientists conducted a review of more than 2900 published studies to provide an updated protocol for the diagnosis and management of the condition